Detection of disseminated tumor cells in peripheral blood of patients with breast cancer: Correlation to nodal status and occurrence of metastases

Gynecologic Oncology

Volumn 92, Issue 1, 2004, Pages 256-261

  Taubert, Helge ^a   Blümke, Karen ^a   Bilkenroth, Udo ^a   Meye, Axel ^a,b   Kutz, Andreas ^a   Bartel, Frank ^a   Lautenschläger, Christine ^a   Ulbrich, Eva Johanna ^a   Nass, Norbert ^a   Holzhausen, Hans Jürgen ^a   Koelbl, Heinz ^a   Lebrecht, Antje ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

AutoMACS; Breast cancer; Cytokeratin expression; Detection of minimal residual disease; Disseminated tumor cells; Magnetic activated cell separation

Indexed keywords

CD45 ANTIGEN; CYTOKERATIN; KERATIN;

ADULT; AGED; ARTICLE; BLOOD; BLOOD ANALYSIS; BREAST CARCINOMA; BREAST TUMOR; CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPLETION; DISSEMINATED CANCER; EVALUATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOMAGNETIC SEPARATION; LEUKOCYTE; LYMPH NODE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; PATHOLOGY; PRIORITY JOURNAL; TECHNIQUE; TUMOR CELL; TUMOR EMBOLISM;

EID: 9144246920     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2003.09.009     Document Type: Article

References (38)

1. Karrison T.G., Ferguson D.J., Meier P. Dormancy of mammary carcinoma after mastectomy. J. Natl. Cancer Inst. 91:1999;80-85.
2. Braun S., Pantel K. Clinical significance of occult metastatic cells in bone marrow of breast cancer patients. Oncologist. 6:2001;125-132.
3. von Knebel Doeberitz M., Lacroix J. Nucleic acid based techniques for the detection of rare cancer cells in clinical samples. Cancer Metastasis Rev. 18:1999;43-64.
4. Pantel K., Cote R.J., Fodstad O. Detection and clinical importance of micrometastatic disease. J. Natl. Cancer Inst. 91:1999;1113-1124.
5. Diel I.J., Solomayer E.F., Bastert G. Micrometastatic cells in the bone marrow of patients with breast carcinoma. Radiologe. 40:2000;681-687.
6. Zehentner B.K. Detection of disseminated tumor cells: strategies and diagnostic implications. Expert Rev. Mol. Diagn. 2:2002;41-48.
7. Zippelius A., Kufer P., Honold G., Kollermann M.W., Oberneder R., Schlimok G.et al. Limitations of reverse-transcriptase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow. J. Clin. Oncol. 15:1997;1702-1708.
8. Jung R., Petersen K., Kruger W., Wolf M., Wagener C., Zander A.et al. Detection of micrometastasis by cytokeratin 20 RT-PCR is limited due to stable background transcription in granulocytes. Br. J. Cancer. 81:1999;870-873.
9. Naume B., Borgen E., Nesland J.M., Beiske K., Gilen E., Renolen A.et al. Increased sensitivity for detection of micrometastases in bone-marrow/ peripheral-blood stem-cell products from breast-cancer patients by negative immunomagnetic separation. Int. J. Cancer. 78:1998;556-560.
10. Maas R.A., Bruning P.F., Breedijk A.J., Top B., Peterse H.L. Immunomagnetic purification of human breast carcinoma cells allows tumor-specific detection of multidrug resistance gene 1-mRNA by reverse transcriptase polymerase chain reaction in fine-needle aspirates. Lab. Invest. 72:1995;760-764.
11. Garau D., Regazzi E., Savoldo B., Sammarelli G., Rizzoli V., Carlo-Stella C. Detection of breast cancer cells using magnetic cell separation (MACS) system: implications for stem cell purging. Eur. J. Histochem. 41(Suppl 2):1997;17-18.
12. Martin V.M., Siewert C., Scharl A., Harms T., Heinze R., Ohl S.et al. Immunomagnetic enrichment of disseminated epithelial tumor cells from peripheral blood by MACS. Exp. Hematol. 26:1998;252-264.
13. Racila E., Euhus D., Weiss A.J., Rao C., McConnell J., Terstappen L.W.et al. Detection and characterization of carcinoma cells in the blood. Proc. Natl. Acad. Sci. U. S. A. 95:1998;4589-4594.
14. Engel H., Kleespies C., Friedrich J., Breidenbach M., Kallenborn A., Schondorf T.et al. Detection of circulating tumour cells in patients with breast or ovarian cancer by molecular cytogenetics. Br. J. Cancer. 81:1999;1165-1173.
15. Krag D.N., Ashikaga T., Moss T.J., Kusminsky R.E., Feldman S., Carp N.Z.et al. Breast cancer cells in the blood: a pilot study. Breast J. 5:1999;354-358.
16. Krüger W., Tögel F., Rösing S., Zander A.R. Improvement of breast cancer cell detection by immunomagnetic enrichment. Cytotherapy. 1:1999;135-139.
17. Zhong X.Y., Kaul S., Lin Y.S., Eichler A., Bastert G. Sensitive detection of micrometastases in bone marrow from patients with breast cancer using immunomagnetic isolation of tumor cells in combination with reverse transcriptase/polymerase chain reaction for cytokeratin 19. J. Cancer Res. Clin. Oncol. 126:2000;212-218.
18. Beitsch P.D., Clifford E. Detection of carcinoma cells in the blood of breast cancer patients. Am. J. Surg. 180:2000;446-448.
19. Naume B., Borgen E., Kvalheim G., Karesen R., Qvist H., Sauer T.et al. Detection of isolated tumor cells in bone marrow in early-stage breast carcinoma patients: comparison with preoperative clinical parameters and primary tumor characteristics. Clin. Cancer Res. 7:2001;4122-4129.
20. Weihrauch M.R., Skibowski E., Draube A., Geller A., Tesch H., Diehl V.et al. Immunomagnetic enrichment and detection of isolated tumor cells in bone marrow of patients with epithelial malignancies. Clin. Exp. Metastasis. 19:2002;617-621.
21. Witzig T.E., Bossy B., Kimlinger T., Roche P.C., Ingle J.N., Grant C.et al. Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopy. Clin. Cancer Res. 8:2002;1085-1091.
22. Bloom H.J.G., Richardson W.W. Histological grading and prognosis in breast cancer. Br. J. Cancer. 11:1957;359-377.
23. Wittekind C., Wagner G. TNM Klassifikation maligner. 1997;Springer, Tumoren.
24. Bilkenroth U., Taubert H., Riemann D., Rebmann U., Heynemann H., Meye A. Detection and enrichment of disseminated renal cell carcinoma cells from peripheral blood by immunomagnetic cell separation. Int. J. Cancer. 92:2001;577-582.
25. Meye A., Bilkenroth U., Schmidt U., Fuessel S., Robel K., Melchior A.M. et al. Isolation and enrichment of urologic tumor cells in blood samples by a semi-automated CD45 depletion autoMACS protocol. Int. J. Oncol. 20:2002;521-530.
26. Remmele W., Stegner H.E. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 8:1987;138-140.
27. Diel I.J., Kaufmann M., Costa S.D., Holle R., von Minckwitz G., Solomayer E.F.et al. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J. Natl. Cancer Inst. 88:1996;1652-1658.
28. Harbeck N., Untch M., Pache L., Eiermann W. Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up. Br. J. Cancer. 69:1994;566-571.
29. Mansi J.L., Gogas H., Bliss J.M., Gazet J.C., Berger U., Coombes R.C. Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study. Lancet. 354:1999;197-202.
30. Braun S., Pantel K., Muller P., Janni W., Hepp F., Kentenich C.R.et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II or III breast cancer. N. Engl. J. Med. 342:2000;525-533.
31. Solomayer E.F., Diel I.J., Salanti G., Hahn M., Gollan C., Schutz F.et al. Time independence of the prognostic impact of tumor cell detection in the bone marrow of primary breast cancer patients. Clin. Cancer Res. 7:2001;4102-4108.
32. Hu X.C., Wang Y., Shi D.R., Loo T.Y., Chow L.W. Immunomagnetic tumor cell enrichment is promising in detecting circulating breast cancer cells. Oncology. 64:2003;160-165.
33. Kim S.J., Ikeda N., Shiba E., Takamura Y., Noguchi S. Detection of breast cancer micrometastases in peripheral blood using immunomagnetic separation and immunocytochemistry. Breast Cancer. 8:2001;63-69.
34. Kraeft S.K., Sutherland R., Gravelin L., Hu G.H., Ferland L.H., Richardson P.et al. Detection and analysis of cancer cells in blood and bone marrow using a rare event imaging system. Clin. Cancer Res. 6:2000;434-442.
35. Landys K., Persson S., Kovarik J., Hultborn R., Holmberg E. Prognostic value of bone marrow biopsy in operable breast cancer patients at the time of initial diagnosis: results of a 20-year median follow-up. Breast Cancer Res. Treat. 49:1998;27-33.
36. Kasimir-Bauer S., Oberhoff C., Sliwinska K., Neumann R., Schindler A.E., Seeber S. Evaluation of different methods for the detection of minimal residual disease in blood and bone marrow of patients with primary breast cancer: importance for clinical use? Breast Cancer Res. Treat. 69:2001;123-132.
37. Krüger W., Datta C., Badbaran A., Togel F., Gutensohn K., Carrero I.et al. Immunomagnetic tumor cell selection-implications for the detection of disseminated cancer cells. Transfusion. 40:2000;1489-1493.
38. Martin K.J., Graner E., Li Y., Price L.M., Kritzman B.M., Fournier M.V. et al. High-sensitivity array analysis of gene expression for the early detection of disseminated breast tumor cells in peripheral blood. Proc. Natl. Acad. Sci. U. S. A. 98:2001;2646-2651.